Search Videos and More
News
Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
The Dana-Farber-co-led phase 3 IMvigor011 trial results show that periodic ctDNA screening after surgery can help guide a decision to begin adjuvant immunotherapy.
News
ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors
Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy.
News
Novel Treatment Combination Improves Progression-Free Survival in Metastatic, Estrogen-Receptor-Positive HER-2-Negative Breast Cancer
Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach.
News
Chemotherapy Combination Boosts Overall Survival in Patients with EGFR-mutant Non-Small Cell Lung Cancer
Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib alone.
News
Dana-Farber Research News 10.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 16 - September 30.
Course
Dana-Farber Center for BRCA & Related Genes Scientific Symposium
Explore the latest advances in hereditary cancer research and care at the Dana-Farber Center for BRCA and Related Genes Scientific Symposium, designed for clinicians and researchers to deepen knowledge of detection, treatment, and ethical issues in BRCA-associated cancers across multiple tumor types.
News
Breast, Lung, and Bladder Cancer Phase 3 Trials led by Dana-Farber Presented at ESMO Congress 2025
Dana-Farber Cancer Institute researchers are leading four studies with important new findings in breast cancer, lung cancer, and bladder cancer at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany.
News
Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 19th Year in a Row
U.S. News & World Report has recognized Dana-Farber/Boston Children's Cancer and Blood Disorders Center as the #3 pediatric cancer program in the nation in its 2025-2026 Best Children's Hospitals report.
Document
Expert Review: Communicating Risk and Uncertainty in the Context of Genomic Testing
The Breast Oncology Center developed this reference for providers based on a presentation by Professor Dame Lesley Fallowfield given on October 23, 2024.
Document
Tip Sheet: QTc Monitoring in Breast Cancer Patients
The Breast Oncology Center developed this reference for QTc monitoring for breast cancer patients based on a presentation given on October 16, 2024, by Anju Nohria, MD, MSc, director of the Cardio-Oncology Program at Dana-Farber Brigham Cancer Center
Document
Tip Sheet: Adrenal Insufficiency in Breast Cancer Patients
The Breast Oncology Center developed this reference for providers treating breast cancer patients with adrenal insufficiency in July 2025.
News
Dana-Farber Research News 10.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 1 through September 15.